These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29684468)

  • 21. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
    Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
    Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum bile acid level and fatty acid composition in Chinese children with non-alcoholic fatty liver disease.
    Lu LP; Wan YP; Xun PC; Zhou KJ; Chen C; Cheng SY; Zhang MZ; Wu CH; Lin WW; Jiang Y; Feng HX; Wang JL; He K; Cai W
    J Dig Dis; 2017 Aug; 18(8):461-471. PubMed ID: 28585279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.
    Liu J; Wang G; Jia Y; Xu Y
    Diabetes Metab Res Rev; 2015 May; 31(4):329-35. PubMed ID: 25066109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. THE ROLE OF BILE ACIDS IN THE REGULATION OF LIPID AND CARBOHYDRATE METABOLISM IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND DIABETES TYPE2.
    Zvenigorodskaya LA; Petrakov AV; Nilova TV; Varvanina GG; Lychkova AE
    Eksp Klin Gastroenterol; 2016; (11):31-34. PubMed ID: 29889442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dietary fat composition shapes bile acid metabolism and severity of liver injury in a pig model of pediatric NAFLD.
    Manjarín R; Dillard K; Coffin M; Hernandez GV; Smith VA; Noland-Lidell T; Gehani TR; Smart HJ; Wheeler K; Sprayberry KA; Edwards MS; Fanter RK; Glanz H; Immoos C; Santiago-Rodriguez TM; Blank JM; Burrin DG; Piccolo BD; Abo-Ismail M; La Frano MR; Maj M
    Am J Physiol Endocrinol Metab; 2022 Sep; 323(3):E187-E206. PubMed ID: 35858244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bile Acid Alterations Characterize the Early Onset and Progression of Nonalcoholic Fatty Liver Disease in Young Mice Fed with High Fat and Fructose Diet.
    Xiang W; Liu A; Xu C; Zhang D; Li W; Ni Y
    Mol Nutr Food Res; 2023 Jun; 67(11):e2200636. PubMed ID: 36938649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids.
    Sun Q; Xin X; An Z; Hu Y; Feng Q
    Front Cell Infect Microbiol; 2022; 12():854879. PubMed ID: 35356532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y; Chen L; Wang H; Narisi B; Chen B
    J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
    Friedrich D; Marschall HU; Lammert F
    BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Farnesoid X receptor modulators 2014-present: a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the alternative bile acid synthetic pathway for metabolic diseases.
    Jia W; Wei M; Rajani C; Zheng X
    Protein Cell; 2021 May; 12(5):411-425. PubMed ID: 33252713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease.
    Ni M; Zhang B; Zhao J; Feng Q; Peng J; Hu Y; Zhao Y
    Biomed Pharmacother; 2019 May; 113():108778. PubMed ID: 30897538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease.
    Jahnel J; Zöhrer E; Alisi A; Ferrari F; Ceccarelli S; De Vito R; Scharnagl H; Stojakovic T; Fauler G; Trauner M; Nobili V
    J Pediatr Gastroenterol Nutr; 2015 Jul; 61(1):85-90. PubMed ID: 25729888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
    Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
    J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bile acids and sphingolipids in non-alcoholic fatty liver disease.
    Jackson KG; Way GW; Zhou H
    Chin Med J (Engl); 2022 May; 135(10):1163-1171. PubMed ID: 35788089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
    Tiessen RG; Kennedy CA; Keller BT; Levin N; Acevedo L; Gedulin B; van Vliet AA; Dorenbaum A; Palmer M
    BMC Gastroenterol; 2018 Jan; 18(1):3. PubMed ID: 29304731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice.
    Saraswathi V; Perriotte-Olson C; Ganesan M; Desouza CV; Alnouti Y; Duryee MJ; Thiele GM; Nordgren TM; Clemens DL
    J Nutr Biochem; 2017 Apr; 42():149-159. PubMed ID: 28187366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microbial metabolites in non-alcoholic fatty liver disease.
    Zhou D; Fan JG
    World J Gastroenterol; 2019 May; 25(17):2019-2028. PubMed ID: 31114130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
    Steinacher D; Claudel T; Trauner M
    Dig Dis; 2017; 35(3):282-287. PubMed ID: 28249257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.